Can a diabetes drug help teens lose weight? new study investigates
NCT ID NCT06852391
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether adding the drug semaglutide (Wegovy®) to a behavioral lifestyle program helps teenagers with obesity lose weight and adapt their metabolism. About 74 teens aged 12-17 will be split into two groups: one gets the lifestyle program alone for 6 months, then adds semaglutide; the other gets both from the start. Researchers will measure how the body's energy use changes, aiming to find better weight management strategies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- semaglutide (Wegovy®)
- What this could lead to
- If successful, this could show that combining semaglutide with a lifestyle program is more effective for weight management in teens than lifestyle changes alone.
- What could go wrong
- This is a small, early-phase study (74 participants) focused on metabolic changes, not long-term weight loss or safety. Semaglutide can cause side effects like nausea and vomiting, and results may not apply to all teens with obesity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 74 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Youth aged 12-17 years * Diagnosed with obesity (BMI ≥2 standard deviations above WHO Reference median) * Enrolled in Growing Health Weight Management or Next Step pediatric clinics (ie. have at least one year of the program remaining). Exclusion Criteria: * Any contraindications for MRI (i.e. claustrophobia, implanted metal, metallic injuries recent tattoo or weight \>300lb. Ineligible for imaging visit only. * Use of atypical anti-psychotics. * Use of the following medication classes: (i.e. Beta-blocker medications, Steatogenic medications, Anti-hyperglycemic medications, HIV drugs, Antidepressants, anxiolytic drugs, anti-psychotic drugs, Thyroid drugs, Antiemetic or amphetamine, dextromethorphan and metoclopramide.) * Elevated alanine aminotransferase (ALT) \> 5 x upper range of normal at screening. * Use of glucose lowering or any anti-obesity medication in the previous 3 months. * Known monogenic, syndromic or hypothalamic causes of obesity. * Diagnosis of type 1 or 2 diabetes mellitus. * Prior bariatric surgery or liver transplantation. * Alcohol intake exceeding 3 drinks per week or reported cannabis use. * Recent history of cigarette smoking (previous 3 months) - ineligible for imaging only. * History or family history of multiple endocrine neoplasia 2 or medullary thyroid cancer. * History of pancreatitis. * Presence of untreated endocrine disorder. * History of an eating disorder and / or history of suicidal ideation * History of a cardiac condition that precludes exercise testing or unable to have exercise testing done in the GHWM pediatric clinic, inability to use a cycle ergometer. Participant who does not have a peak power value obtained in the GHWM pediatric clinic Female who is pregnant, breast-feeding or intends to become pregnant. Female who refuses to use a means of contraception if sexually active. Participation in any interventional clinical study within 90 days before screening.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity (disorder) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
McMaster University
RECRUITINGHamilton, Ontario, L8S 4L8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria supplement tested against memory loss in obesity
- Can a simple questionnaire capture the true toll of metabolic surgery?
- Brain scans probe how obesity may shape memory
- Breathing training may boost fitness in teens with learning disabilities
- Can patients power their own obesity research?
- App aims to supercharge GLP-1 weight-loss drugs with personalized meal plans